Publisher’s Spotlight: The Citeline Awards Are Open For Entries!

Deadline For Submissions Is 23 February

Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees. 

Stopwatch (shutterstock_157284068)
• Source: Shutterstock

Drug development is a long and arduous process, more likely to fail than not. That is why we hold the Citeline Awards, to honor the remarkable achievements and the efforts made along the way by biopharma companies as well as companies providing services to the industry. Seize the opportunity to bring recognition and raise awareness of your innovative work in research and development.

The deadline for entries is approaching. Entries received before the 23 February deadline carry a $99 fee, which can be applied toward attendance at the event; the fee for late submissions is $199. Guidance on the submission process is available on the Citeline Awards website. All entries are judged by an independent panel of industry experts.

The 12 award categories recognize a range of activities:

  • Excellence in Rare Disease Drug Development
  • Best Use of Artificial Intelligence in Clinical Trials
  • Excellence in Patient Recruitment and Engagement
  • Best Patient-Facing Technology Initiative
  • Best Sponsor-Facing Technology Initiative
  • Most Successful Early Phase Research (Preclinical & Phase I)
  • Champion of Diversity & Inclusion in Clinical Trials
  • Clinical Partnership of the Year
  • Most Innovative Start-Up Company
  • Clinical Research Team of the Year
  • Excellence in Use of Real-World Data/Evidence
  • Clinical Trial Result of the Year (open to pharma and biotech companies only)

The Citeline Awards will be held 8 May at the Westin Boston Seaport District Hotel. Please join us in celebrating the global community of biopharmaceutical R&D!

More from R&D

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By 

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.